.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,034,394

« Back to Dashboard

Claims for Patent: 5,034,394

Title: Therapeutic nucleosides
Abstract:The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
Inventor(s): Daluge; Susan M. (Chapel Hill, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/455,201
Patent Claims: 1. A compound of formula (I): ##STR4## wherein R.sup.3 represents hydrogen or C.sub.1-6 alkyl; R.sup.6 represents C.sub.3-8 cycloalkyl, and R.sup.7 represents a hydrogen atom or a branched or straight chain C.sub.1-6 alkyl; or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

2. A compound, ester or salt of formula (I) according to claim 1 in which R.sup.3 is hydrogen, R.sup.6 is C.sub.3-6 cycloalkyl and R.sup.7 is methyl or hydrogen.

3. A compound according to claim 2 in which R.sup.6 is cyclopropyl.

4. A compound of formula (I) according to claim 1 selected from:

(-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-met hanol and

(-)-cis-4-[2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-cyclopentene -1-methanol or

racemic or partially resolved mixtures with the (+)-cis enantiomers thereof.

5.

5. (.+-.)-cis-4-[2-amino-6-(cyclopropylamino-9H-purin-9-yl]-2-cyclopentene- 1-methanol.

6. (-)-cis- 4-[2-amino-6-(cyclopropylamino-9H-purin-9-yl]-2-cyclopentene-1-methanol.

7. A pharmaceutically acceptable salt of a compound according to claims 5 or 6.

8. A pharmaceutically acceptable ester of a compound according to claims 5 or 6.

9. A compound of formula (I) according to claim 1 wherein the pharmaceutically acceptable ester is a mono-, di-, or tri-phosphate ester or a pharmaceutically acceptable salt thereof.

10. A compound of formula (I) according to claim 1 wherein the pharmaceutically acceptable ester is the L-valinate or a salt thereof.

11. A compound, ester or salt of claim 3, in which the pharmaceutically acceptable ester is a mono-, di, or tri-phosphate ester or a pharmaceutically acceptable salt thereof.

12. A compound of the formula (I): R1 ? ? ##STR5## wherein R.sup.7 is hydrogen, R.sup.6 is cyclopropyl and R.sup.3 is hydrogen or a pharmaceutically acceptable salt thereof.

13. A compound of the formula (I): ##STR6## wherein R.sup.7 is methyl, R.sup.6 is cyclopropyl and R.sup.3 is hydrogen or a pharmaceutically acceptable salt thereof.

14. A tablet or capsule containing the compound of claim 12.

15. A tablet or capsule containing the compound of claim 13.

16. (.+-.)-cis-4-[2-amino-6-(cyclopropylmethylamino)-9H-puri n-9-yl]-2-cyclopentene-1-methanol.

17. (-)-cis-4-[2-amino-6-(cyclopro pylmethylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol.

18. A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

19. A formulation according to claim 18 wherein the compound of formula (I) is selected from:

(-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-met hanol and

(-)-cis-4-[2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-cyclopentene -1-methanol or

racemic or partially resolved mixtures with the (+)-cis enantiomers thereof.

20. A tablet or capsule containing 50 to 700 mg of a compound according to claims 5 or 6 or a pharmaceutically acceptable salt or a pharmaceutically acceptable ester thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc